Nom du produit:6,7-Dihydro-2H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3(5H)-one

IUPAC Name:3,4-diazatricyclo[9.4.0.0²,⁷]pentadeca-1(15),2,6,11,13-pentaen-5-one

CAS:25823-52-3
Formule moléculaire:C13H12N2O
Pureté:95%
Numéro de catalogue:CM324062
Poids moléculaire:212.25

Unité d'emballage Stock disponible Prix($) Quantité
CM324062-250mg in stock Ƕưŵ
CM324062-1g 1-2 Weeks ǜũŵ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:25823-52-3
Formule moléculaire:C13H12N2O
Point de fusion:-
Code SMILES:O=C1C=C(CCCC2=CC=CC=C23)C3=NN1
Densité:
Numéro de catalogue:CM324062
Poids moléculaire:212.25
Point d'ébullition:
N° Mdl:MFCD16871353
Stockage:

Column Infos

Bemcentinib
Bemcentinib is a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. Extensive studies confirm the ability to combine bemcentinib with immune checkpoint inhibitors, chemotherapies and targeted therapies with the goal of improving a patient’s immune response and delaying the development of chemoresistance. Bemcentinib is currently being investigated in combination with immune checkpoint inhibition and chemotherapy in first line NSCLC patients harboring mutations in the STK11 gene, a known prognostic factor of poor response to existing therapies.

Related Products